Supplementary information – Table of contents

- **Table S1.** Commercial products used in this study.
- **Table S2.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of BNT162b2 group (n = 6).
- **Table S3.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of mRNA-1273 group (n = 16).
- **Table S4.** Comparison of mean titers in mRNA-1273 group participants based on a history of previous COVID-19.
- **Table S5**. Quantitative titers on each assay in patients on biologics/immunosuppressants.
- **Fig. S1.** Box-whisker plots demonstrating the spread of only positive quantitative (titer) results for each vaccine group for the (a) RBD IgG assay; (b) Trimeric S IgG assay; and (c) nAb assay.

Table S1. Commercial products used in this study.

Item	Description	Commercial affiliation	
BNT162b2 vaccine	mRNA vaccine	Pfizer	
		(New York, NY, USA)	
mRNA-1273 vaccine	mRNA vaccine	Moderna Messenger	
		Therapeutics	
		(Cambridge, MA, USA)	
Serology assay	SARS-CoV-2 IgG targeting	Abbott	
(Abbott Architect)	the nucleocapsid protein	(Chicago, IL, USA)	
Serology assay	SARS-CoV-2 IgG targeting	Abbott	
(Abbott Architect)	the receptor binding domain	(Chicago, IL, USA)	
	(RBD)		
Serology assay	SARS-CoV-2 IgG targeting	DiaSorin	
(DiaSorin Liaison)	the S1/S2 regions of the	(Saluggia, Italy)	
	spike protein		
Serology assay	SARS-CoV-2 neutralizing	GenScript	
(manual assay)	antibody (nAb) preventing	(Piscataway, NJ, USA)	
	RBD and angiotensin-		
	converting enzyme 2 (ACE-		
	2)		
Electronic medical record	Epic EMR	Epic	
(EMR)		(Verona, WI, USA)	
Statistical software	Stata Version 16.1	StataCorp	
		(College Station, TX, USA)	

Table S2. Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of BNT162b2 group (n = 6).

Case	Days	Anti-N IgG	Anti-N IgG result	Anti-N IgG result
	between COVID-19	result at	2-weeks post first	prior to second
	diagnosis and first	baseline ^b	dose of vaccine	dose of vaccine
	vaccine dose ^a			
Case	27	+	+	ND
1				
Case	45	+	+	+
2				
Case	46	+	-	ND
3				
Case	118	+	+	ND
4				
Case	-7	-	ND	+
5				
Case	-34	-	-	-
6 ^c				

Abbreviations: ND – not done; + positive; - negative

^aA negative value refers to the diagnosis of COVID-19 being made after the first dose of vaccine. All SARS-CoV-2 diagnosis were confirmed using PCR testing from a nasopharyngeal or oropharyngeal swab collected due to symptoms.

^bQualitative results on the RBD IgG, Trimeric S IgG, and GenScript nAb assays were concordant with the Anti-N IgG result at baseline for all six cases.

^cConfirmed COVID-19 positive nine days after second dose of BNT162b2 vaccine.

Table S3. Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of mRNA-1273 group (n = 16).

Case	Days between COVID-19 diagnosis and first vaccine dose ^a	Anti-N IgG result 2- weeks post first vaccine dose ^b	Anti-N IgG result prior to 2 nd dose of vaccine ^b
Case 1	18	+	ND
Case 2	18	ND	ND
Case 3	22	ND	ND
Case 4	27	+	+
Case 5	34	ND	+
Case 6	35	ND	ND
Case 7	41	ND	-
Case 8	41	ND	ND
Case 9	45	+	+
Case 10	45	ND	ND
Case	48	ND	ND
Case	73	+	+
Case	73	+	-
Case 14	73	-	-
Case 15	76	+	-
Case 16	76	ND	+

Abbreviations: ND – not done due to shortage of assay reagents; + positive; - negative ^aAll SARS-CoV-2 diagnosis were confirmed using PCR testing from a nasopharyngeal or oropharyngeal swab collected due to symptoms.

^bAll of these patients were found to be positive in one or more of either RBD IgG, Trimeric S IgG, or nAb titer.

Table S4. Comparison of median titers (IQRs) in mRNA-1273 group participants based on a history of previous COVID-19.

Time point	Assay	COVID-19 No prior histo		p-value
		Recovered	of COVID-19	
2-weeks post Trimeric S-IgG		785	14.4	0.0002
first vaccine			(0-40.3)	
dose		(n = 7)	(n = 25)	
	RBD IgG 40		74.7	< 0.0001
	(AU/mL)	(28,534.6-	(3.6-429.7)	
		40,000)	(n = 25)	
		(n = 7)		
	nAb	37,672	0	0.0009
	(ng/mL)	(1,233.8-	(0-189.6)	
		107,194.2)	(n = 25)	
		(n = 7)		
Pre-2 nd vaccine	Trimeric S-IgG	800	58.2	< 0.0001
dose	(AU/mL)	(651-800)	(13.8-113)	
		(n = 16)	(n = 31)	
	RBD IgG	40000	280.9	< 0.0001
	(AU/mL)	(37257.3-40000)	(88.1-909.5)	
		(n = 9)	(n = 28)	
	nAb	33,874.2	185.4	< 0.0001
	(ng/mL)	(2,179.4-	(0-386.2)	
		48,052.8)	(n = 32)	
		(n = 16)		

 Table S5.
 Quantitative titers on each assay in patients on biologics/immunosuppressants.


Timing of blood sample / Assay	Participant 1 (BNT162b2)	Participant 2 (BNT162b2)	Participant 3 (BNT162b2)	Participant 4 (BNT162b2)	Participant 5 ^a (mRNA-1273)	
Baseline blood	Baseline blood sample					
RBD IgG (AU/mL)	6.8	0	0	0	ND	
Trimeric S IgG (AU/mL)	1.9	1.9	1.9	1.9	ND	
nAb (ng/mL)	0	0	0	0	ND	
2-week blood	sample					
RBD IgG (AU/mL)	270.6	127.4	492.9	641.4	7,541.3	
Trimeric S IgG (AU/mL)	56.3	17.4	119	139	371	
nAb (ng/mL)	0	0	477	250.2	2,534.2	
Pre-2 nd dose b	Pre-2 nd dose blood sample					
RBD IgG (AU/mL)	ND	247.2	ND	1,092.8	8,210.6	
Trimeric S IgG (AU/mL)	ND	23.4	ND	162	428	
nAb (ng/mL)	ND	281.4	ND	540.2	3,020.4	

Abbreviations: ND – not done.


aParticipant 5 is COVID-19 recovered (received first dose of mRNA-1273 vaccine 73 days) post date of COVID-19 diagnosis).

Figure S1:

a



b



c




Fig. S1. Box-whisker plots demonstrating the spread of only positive quantitative (titer) results for each vaccine group for the (a) RBD IgG assay; (b) Trimeric S IgG assay; and (c) nAb assay.